Every 10-Q that NORTHWEST BIOTHRPUTCS INC (NWBO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NWBO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NWBO filings page.
Northwest Biotherapeutics, Inc. reported a net loss of $12.3 million for the six months ended June 30, 2026, compared with a net loss of $34.7 million a year earlier. Revenue was limited, at $1.3 million, primarily from research and other income, while the company remains pre-commercial.
Total assets were $75.9 million, against total liabilities of $110.7 million and a stockholders’ deficit of $45.2 million. Cash and cash equivalents were only $0.6 million, after using $19.7 million of cash in operating activities in the first half. Management states there is substantial doubt about the ability to continue as a going concern without additional financing.
The company continues to focus on its DCVax-L dendritic cell therapy, having completed a Phase 3 glioblastoma trial and submitted a Marketing Authorization Application to the UK MHRA, which remains under review. Operations are being funded through equity issuances, notes payable, and convertible notes, including subsequent financing of $4.9 million via a Yorkville convertible note and access to a $50 million standby equity subscription agreement.
Northwest Biotherapeutics reported a smaller net loss but remains financially constrained in Q1 2026. The company generated $494,000 of revenue, mainly from research services, while research and development expenses were $4.9 million and general and administrative costs were $6.5 million, both down sharply from the prior year.
Other income, including a $2.25 million litigation settlement gain and fair value adjustments on derivatives and convertible notes, reduced the net loss to $3.1 million from $19.3 million. Cash and cash equivalents were $1.8 million against total liabilities of $118.1 million and a stockholders’ deficit of $50.5 million, and management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing.
Northwest Biotherapeutics (NWBO) filed its Q3 2025 10‑Q reporting continued losses and tight liquidity. The company posted a net loss of $26.8 million for the quarter and $61.6 million year‑to‑date, on research and other revenue of $200,000 for the quarter. Operating expenses were $14.5 million in Q3, split between R&D $7.5 million and G&A $7.1 million.
Cash and equivalents were $4.56 million at September 30, 2025, after $30.0 million net cash used in operations year‑to‑date. Total liabilities were $125.9 million and stockholders’ deficit was $(108.6) million. The company disclosed substantial doubt about its ability to continue as a going concern. Financing activities included issuing common stock for $17.3 million net cash and converting debt and interest into 107.0 million shares ($27.6 million non‑cash). Convertible notes measured at fair value rose to $50.6 million, and interest expense was $2.6 million in Q3. NWBO agreed to acquire Advent BioServices on August 27, 2025 and closed the deal on October 24, 2025. Shares outstanding were 1,540,682,082 as of November 13, 2025.